DocGo Lowers 2026 Revenue Guidance to About $300 Million

Medical services provider DocGo Inc. reduced its 2026 revenue forecast to about $300 million as it works to restructure unprofitable operations, while keeping its projected adjusted EBITDA loss unchanged.

The new revenue target, announced Nov. 9, replaces a range of $305 million to $310 million. DocGo still expects an adjusted EBITDA loss of $17 million to $22 million for the year. Its restructuring is aimed at eliminating or changing business lines that do not contribute positively to adjusted EBITDA.

Third-quarter revenue rose to $73.4 million from $70.8 million a year earlier. The adjusted EBITDA loss narrowed to $3.2 million from $7.2 million in the year-earlier quarter.

DocGo’s board also began a search to replace CEO Lee Bienstock. His contract expires Dec. 31, but he will remain CEO until a successor is appointed and stay with the company through at least March 31, 2027.

The guidance excludes any contribution from the pending Hicuity Health acquisition. DocGo expects the transaction to close in late November or early December.